One of the most nerve-wracking questions you can ask a medtech company is: “When can you launch?”

A simple commercial question is where the pressure usually starts.

For Western medtech companies, the China launch date often appears in the commercial forecast before the regulatory pathway has been fully defined.

If you have watched “The Dropout” mini-series, some may perceive it as a story about an ambitious woman who tried to build a biotechnology company, “Theranos” in Silicon Valley, but eventually failed.

But for regulatory and quality professionals, this series demonstrates one of the more uncomfortable lessons.

This is the case of Theranos, which developed a faulty blood-testing technology that endangered lives.

Can you imagine the company was valued at $9 billion at its peak?

🍜 Ticking Time Bomb Scenario

Timelines become dangerous when they are built around what investors want to hear rather than what the evidence supports.

China's market access has its own version of this problem.

No one needs to be Theranos to fall into it.

A manufacturer may have a functional medical device, a valid CE mark or FDA clearance, a strong technical file, and serious commercial interest from China.

The risk is not deliberate deception here.

The risk is that one quietly assumes China will accept the same technical documents, testing reports, and labels that worked elsewhere.

That assumption can become costly.

The goal is not to “move slowly.”

Competition and innovation still need speed.

But speed without verification creates a compliance or safety concern that someone will eventually have to pay.

Either the company, investors, or patients.

Regulatory teams should challenge four assumptions before commercial leadership gives promises to distributors or hospitals.

🍜 Regulatory strategy

Classification is not a translation exercise.

A device that appears straightforward in the EU or US may not fall into the expected category in China.

Classification defines the submission route, testing requirement, and clinical strategy.

It also provides a hint on how long it will take.

Commercial pressure kicks in long before a timeline appears in a forecast.

The pain point for manufacturers is not only “What class is the device?”

It is the alignment of the regulatory strategy, launch plan, and distributor promise.

🍜 Type testing

Many manufacturers underestimate the timeline of local testing because they view testing as an administrative step.

Additional type testing is the critical path to show compliance with applicable Chinese standards and product technical requirements.

That means the question is not only whether the product has already passed IEC, ISO, EU MDR, or FDA-related testing.

It is often a timeline driver where the foreign manufacturer misses the most.

This is where “we already tested this globally” becomes a weak answer.

The pain point is not testing itself. It is discovering testing gaps after leadership has already promised market entry.

The product may fail to meet stricter parameters if the gap assessment has not been evaluated early.

Need a gap assessment? Let’s talk. 

🍜 Clinical evaluation

Your CE or FDA evidence does not automatically solve clinical evaluation in China.

A common assumption is that the translation of existing clinical data, PMCF, literature, and equivalence analysis will be enough.

Not entirely.

NMPA issued multiple clinical evaluation technical guidance documents.

The considerations of whether clinical trials or clinical evaluation are needed, and which predicate you need for China.

The China-specific issue is mapping.

This is often discovered too late because the global dossier looks “complete.”

The submission dossier needs a China story, not just a global archive.

Completeness is not the same as China review readiness.

Theranos is an extreme example of what happens when narrative outruns evidence.

🍜 Labeling

Labeling, IFU, packaging, and UDI are often treated as late-stage launch operations.

In fact, labeling information is highly dependent on the results from local type testing.

It is not only about translation.

NMPA has announced that medical devices must implement a UDI before they can be imported into China.

The UDI implementation deadline of Class I IVD reagents and Class II medical devices (including IVDs) is June 1st, 2027.

The UDI requirement will take effect on June 1st, 2029 for all other Class I medical devices.

For Western manufacturers, the practical issue is coordination between testing, submission dossier, labeling, packaging, and database preparation.

🍜 Checklist

The problem is rarely that the global dossier has no evidence.

It is just that the evidence was built for another regulatory conversation.

A China dossier is not just an archive of global documents. It is a regulatory argument made to Chinese reviewers under China’s rules.

Ask yourself and pressure-test the assumptions before a launch date is put in front of investors and distributors:

• Is the regulatory strategy clearly defined?

• Are the China standards and gaps known?

• Does the clinical evidence meet local requirements and have a predicate?

• Are labeling, IFU, UDI, and product information database ready for China?

Understanding this will prevent the business from selling a timeline that regulatory, quality, and clinical evidence cannot support.

In Theranos, the timeline kept moving even when the evidence was not ready.

Before you commit to a China launch timeline, pressure-test the assumptions behind it.

That is exactly where a focused China regulatory gap assessment can protect both compliance and credibility.

That’s all for today.

🍜 Our Principles 🍜

Medtech Chopsticks brings clarity to your China market access strategy and regulatory compliance.

We enable faster, clearer decision-making in your company.

We support small or mid-sized manufacturers in navigating NMPA registration, compliance risks, and a constantly evolving regulatory framework.

Book your first call to understand where you stand.  

Forwarded this email? Sign up here
Follow me on LinkedIn

Disclaimer: This content is created solely in my personal interest and does not reflect the views, opinions, or policies of my employer or any other organizations I am affiliated with. Neither I nor my employer is liable for any use of this content. This newsletter does not compete with my employer’s interests. Any references to regulatory updates or guidance are based on publicly available information and are not intended to infringe upon proprietary or confidential content.